Monforte, VictorUssetti, PiedadCastejon, RaquelSintes, HelenaLuz Perez, VirginiaLaporta, RosaliaSole, AmparoManuel Cifrian, JoseMarcos, Pedro J.Redel, JavierLos Arcos, IbaiBerastegui, CristinaAlonso, RodrigoRosado, SilviaEscriva, JuanIturbe, DavidPablo Ovalle, JuanManuel Vaquero, JoseLopez-Meseguer, ManuelMendoza, AlbertoGomez-Olles, Susana2025-01-072025-01-072021-11-010300-2896https://hdl.handle.net/10668/25753Introduction: Immune cell functional assay (ImmuKnow (R)) is a non-invasive method that measures the state of cellular immunity in immunosuppressed patients. We studied the prognostic value of the assay for predicting non-cytomegalovirus (CMV) infections in lung transplant recipients.Methods: A multicenter prospective observational study of 92 patients followed up from 6 to 12 months after transplantation was performed. Immune cell functional assay was carried out at 6, 8, 10, and 12 months.Results: Twenty-three patients (25%) developed 29 non-CMV infections between 6 and 12 months post-transplant. At 6 months, the immune response was moderate (ATP 225-525 ng/mL) in 14 (15.2%) patients and low (ATP = 525 ng/mL). Only 1 of 14 (7.1%) patients with a moderate response developed non-CMV infection in the following 6 months compared with 22 of 78 (28.2%) patients with low response, indicating sensitivity of 95.7%, specificity of 18.8%, positive predictive value (PPV) of 28.2%, and negative predictive value (NPV) of 92.9% (AUC 0.64; p = 0.043). Similar acute rejection rates were recorded in patients with mean ATP >= 225 vs. = 225 vs.enImmune cell assayImmunosuppressionInfectionLung transplantImmunknowAdenosine-triphosphate productionRecurrent hepatitis-cCylex immuknow assayWorking formulationAllograft-rejectionStandardizationExperienceRiskresearch article33551278open access10.1016/j.arbres.2020.12.0241579-2129https://doi.org/10.1016/j.arbres.2020.12.024714984600006